More M&A For Astellas As It Pursues New Mid-Term Goals?
This article was originally published in PharmAsia News
Executive Summary
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.
You may also be interested in...
After Hiccups, Astellas’s Mirabegron On Course For Indian Debut?
Astellas’s overactive bladder drug mirabegron, which previously failed to pass muster in India, has now been cleared by an expert panel in the country, though competition appears to be building up alongside.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.